Table 1.
Baseline characteristics and clinical outcome, IgAN by IgG codeposition
| IgA | IgA + IgG | P-value | |
|---|---|---|---|
| [n = 55 (69%)] | [n = 25 (31%)] | ||
| Clinical characteristics | |||
| Age (years) | 38 (25–47) | 33 (24–40) | 0.129 |
| Gender | 0.802 | ||
| Female | 35% (19) | 40% (10) | |
| Male | 65% (36) | 60% (15) | |
| Race | 0.709 | ||
| Asian | 15% (8) | 12% (3) | |
| Caucasian | 65% (36) | 76% (19) | |
| Other | 20% (11) | 12% (3) | |
| SCr at biopsy (mg/dL) | 1.3 (0.99–2.7) | 1.3 (0.93–2.0) | 0.604 |
| eGFR at biopsya (mL/min/1.73 m2) | 61.4 (27.7–92.1) | 56.0 (28.3–90.5) | 0.944 |
| uPCR at biopsy (g/g) | 1.33 (0.7–4.07) | 0.85 (0.44–2.52) | 0.192 |
| uPCR at biopsyb | 0.425 | ||
| High | 25% (14) | 36% (9) | |
| Low | 75% (41) | 64% (16) | |
| Length of follow-up (months) | 27 (9.0–55.3) | 32 (18.6–48.2) | 0.495 |
| Biopsy characteristics | |||
| Mesangial hypercellularity (M1) | 67% (36) | 79% (19) | 0.297 |
| Endocapillary hypercellularity (E1) | 35% (19) | 58% (14) | 0.082 |
| Segmental sclerosis (S1) | 74% (40) | 75% (18) | 1.000 |
| Interstitial fibrosis (T) | 0.553 | ||
| T0 | 52% (28) | 50% (12) | |
| T1 | 22% (12) | 33% (8) | |
| T2 | 26% (14) | 17% (4) | |
| Presence of crescents/segmental glomerular necrosis | 25% (14) | 36% (9) | 0.425 |
| Immune deposit localization | 0.584 | ||
| Mesangium + PCWs | 29% (16) | 20% (5) | |
| Mesangium only | 71% (39) | 80% (20) | |
| Treatment | |||
| Use of ACEi or ARB | 83% (45) | 96% (23) | 0.162 |
| Use of prednisone and/or cytotoxic agents | 40% (21) | 46% (11) | 0.803 |
| Use of fish oil | 38% (20) | 42% (10) | 0.806 |
| Outcome | |||
| Number of patients reaching combined outcomec | 29% (16) | 32% (8) | 0.823 |
| eGFR at follow-upa (mL/min/1.73 m2) | 69.0 (23.5–94.6) | 49.7 (25.0–97.0) | 0.768 |
| uPCR at follow-up (g/g) | 0.37 (0.1–0.6) | 0.54 (0.2–1.27) | 0.145 |
| uPCR at follow-upb | 0.346 | ||
| High | 24% (9) | 39% (7) | |
| Low | 76% (28) | 61% (11) | |
| Slope of eGFRa (mL/min/1.73 m2)/month | −0.05 ± 1.9 | −0.03 ± 0.82 | 0.980 |
Values are presented as median (interquartile range) and percentage and absolute numbers.
a
eGFR based of a total of 65 patients with follow-up and removal of outliers; slope of eGFR: change of eGFR over the observation period.
b
High is defined as a uPCR ≥1; low is defined as a uPCR <1.
c
Combined outcome: doubling of SCr concentration, renal replacement therapy, kidney transplantation or death.